<![CDATA[Biophoenix Reports Catalogue]]> http://www.biophoenix.com/reports/ beata@biophoenix.com PrestaShop en <![CDATA[Biophoenix Reports Catalogue]]> http://www.biophoenix.com/reports/img/logo.jpg http://www.biophoenix.com/reports/ <![CDATA[Apoptosis: Opportunities in Cancer and Other Diseases - $1,890.00 ]]> <img src="http://www.biophoenix.com/reports/img/p/723-805-small.jpg" title="Apoptosis: Opportunities in Cancer and Other Diseases" alt="thumb" />Apoptosis: Opportunities in Cancer and Other Diseases (February 2009)

This report focuses on apoptosis-modulating drugs in cancer, CNS disorders and chronic inflammation/autoimmunity

]]> <![CDATA[Biosimilars and Biobetters: Positioning for a New Market - $1,890.00 ]]> <img src="http://www.biophoenix.com/reports/img/p/724-807-small.jpg" title="Biosimilars and Biobetters: Positioning for a New Market" alt="thumb" />This report explores trends in the market for biologics and biosimilars and identifies product improvement technologies offering a source of competitive advantage.

*50% discount on this report for SMi's conference attendees* 

]]> <![CDATA[Cancer drugs with apoptotic targets in development (July 2010) - $350.00 ]]> <img src="http://www.biophoenix.com/reports/img/p/982-1045-small.jpg" title="Cancer drugs with apoptotic targets in development (July 2010)" alt="thumb" />Introductory 15% discount on this new publication available until 15 August 2010

Key  information  on  138  targeted apoptotic  drugs  in  anticancer development by a total of  104  companies. These drugs are directed at the products of one or more of over 40 genes involved in apoptosis.

]]>